BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported second quarter 2025 results, producing license revenues of $304,000. Following the transition of commercialization ...

After a prostate cancer diagnosis, the way your doctor describes your cancer can help you understand what to expect next.

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 ...

Plus Therapeutics (PSTV) announced positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid, CSF, Assay Platform at the 2025 ...

Non-specific symptoms can mean many other things, so just because you may exhibit these symptoms, it doesn’t automatically ...

Among patients with advanced gastrointestinal stromal tumors, Gleevec and Mektovi was associated with benefits in progression and survival.

HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and executed. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, HopeAI ...

American Cancer Society Cancer Action Network, American Cancer Society, CAMPAIGN, Congress ,funding for cancer research ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...